drugset / Trial / NCT03779100
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.
Timeline
- Start
- 2018-12-17
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Outcome
Outcome not reported
Stopped: “Protocol modification”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |